Dimensional Fund Advisors LP Invests $1.40 Million in MBX Biosciences, Inc. $MBX

Key Points

• Dimensional Fund Advisors acquired 46,753 shares of MBX Biosciences worth approximately $1.40 million, representing a 0.10% stake. Several other institutional investors also increased or initiated positions.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $75.62; recent targets range from $56 to $90.
• MBX shares opened at $68.57 and have risen sharply from a 12-month low of $9.63, but the company reported a quarterly loss of $0.78 per share, missing estimates by $0.10.

Dimensional Fund Advisors LP acquired a new stake in MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 46,753 shares of the company's stock, valued at approximately $1,396,000. Dimensional Fund Advisors LP owned 0.10% of MBX Biosciences at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in MBX Biosciences during the fourth quarter valued at about $28,000. Russell Investments Group Ltd. increased its stake in MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock valued at $26,000 after acquiring an additional 1,446 shares during the period. Royal Bank of Canada raised its position in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock worth $49,000 after purchasing an additional 572 shares in the last quarter. Strs Ohio lifted its stake in MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company's stock worth $48,000 after purchasing an additional 900 shares during the period. Finally, California State Teachers Retirement System lifted its stake in MBX Biosciences by 64.7% during the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company's stock worth $55,000 after purchasing an additional 689 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MBX shares. Truist Financial upped their price objective on MBX Biosciences from $70.00 to $88.00 and gave the company a "buy" rating in a research note on Monday. Barclays restated an "overweight" rating and set a $88.00 target price on shares of MBX Biosciences in a research report on Friday, August 7th. UBS Group reiterated a "buy" rating and issued a $90.00 price target on shares of MBX Biosciences in a research report on Thursday, July 23rd. Citigroup reiterated an "outperform" rating on shares of MBX Biosciences in a research note on Tuesday, May 12th. Finally, Stifel Nicolaus set a $56.00 price objective on MBX Biosciences in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $75.62.

MBX Biosciences Stock Up 2.2%

NASDAQ:MBX opened at $68.57 on Friday. MBX Biosciences, Inc. has a 12-month low of $9.63 and a 12-month high of $72.64. The stock's fifty day simple moving average is $55.85 and its 200-day simple moving average is $40.94. The firm has a market capitalization of $3.30 billion, a P/E ratio of -28.45 and a beta of 0.10.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.10). As a group, equities research analysts expect that MBX Biosciences, Inc. will post -3.12 earnings per share for the current year.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

Want to see what other hedge funds are holding MBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MBX Biosciences, Inc. (NASDAQ:MBX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source